When examined by site, 68% of the oropharyngeal, 28% of the oral cavity, and 16% of the laryngeal cancers were p16+; p53+ prevalence was 47% in the oropharynx, 46% in the oral cavity, and 59% in the larynx; and 63% of the oropharynx, 15% of the oral cavity, and 9% of the larynx tumors were HPV-HR positive. Here, TP53 is linked to laryngeal carcinoma.